Blog
FMT explained: when faecal microbiota transplant is used
Faecal microbiota transplantation is not a general-purpose “gut reset.” It is a medical therapy that needs a defined clinical goal, screened donor material and a doctor's oversight.
FMT transfers a processed microbial community from carefully screened donor material into a recipient's gastrointestinal tract. The aim is to change the recipient's gut microbial ecosystem in a controlled, medically supervised way.
What FMT is — and what it is not
Formal FMT uses screened and processed donor stool or regulated microbiota products to deliver a microbial community into the gastrointestinal tract. It is a medical intervention with infection-control, donor-screening and regulatory requirements.
Those approaches differ in composition, manufacturing, evidence and regulatory oversight.
Where the evidence stands
FMT has been studied across a range of conditions, and the strength of evidence differs sharply between them. For most proposed uses the question is still open, and results depend on the condition, the preparation and the protocol.
Regulation also varies by country. Some jurisdictions have approved specific microbiota products for narrowly defined uses, while traditional donor-derived FMT follows a different pathway. What is appropriate for an individual should be confirmed at assessment.
| Use | Evidence position |
|---|---|
| Ulcerative colitis | Studied with some positive signals; not standard care |
| Crohn's disease | Investigational |
| Irritable bowel syndrome | Mixed and inconsistent results |
| Obesity and metabolic disease | Investigational; no clinical role |
| Autism, depression, cognitive symptoms | Research only; claims run far ahead of evidence |
| General wellness, detox, longevity | No evidence; not an appropriate use |
FMT can be delivered in different ways
Lower-GI delivery
Colonoscopy or rectal administration can place material directly into the colon, but procedural risks and preparation apply.
Oral microbiota products
Capsule-based regulated products avoid endoscopy but have product-specific indications and preparation instructions.
Upper-GI routes
Tube-based delivery has been used historically but introduces route-specific aspiration and procedural considerations.
The best route depends on the exact product, indication, patient factors and local regulatory pathway — not patient preference alone.
Donor screening is central to safety
Donor material can transmit infectious organisms, including organisms not detected by incomplete screening. Modern protocols therefore use detailed medical and exposure histories plus laboratory testing for relevant enteric pathogens and transmissible infections.
Screening is also time-sensitive rather than one-off. A donor cleared months earlier may have acquired an infection since, which is why established programmes re-screen, quarantine material and release it only once subsequent testing is clear. That process is a substantial part of what distinguishes a regulated product from an informal arrangement.
Apparent health in a donor does not rule out transmissible infection, antimicrobial-resistant organisms or other risks. Formal processing and clinical oversight are essential.
Risks include more than temporary bloating
- Abdominal discomfort, bloating or altered bowel habit
- Procedure-related complications when endoscopy is used
- Aspiration risk with selected upper-GI routes
- Transmission of infectious pathogens or antimicrobial-resistant organisms
- Uncertain long-term transfer of donor-associated metabolic or immune characteristics
FDA safety alerts have documented serious infections linked to inadequately screened donor material, which is why modern donor-screening requirements are stringent. Those cases involved transmission of drug-resistant organisms to vulnerable recipients, and they are the reason the field became considerably more cautious.
The final point on that list deserves attention because it is the least discussed. Transferring an entire microbial community is not the same as administering a defined drug — you are transferring something whose full composition and long-term effects are not completely characterised. Animal work suggesting that metabolic traits can travel with microbiota is a reason for caution about casual use, even if its human relevance remains unclear.
IBS, IBD, obesity, mental health and longevity remain investigational
FMT is being studied in inflammatory bowel disease, irritable bowel syndrome, metabolic disease and other conditions. Results are heterogeneous, and no broad conclusion supports using FMT as a routine treatment for dysbiosis, weight loss, cognitive symptoms or longevity.
An earlier version of this article overstated those possibilities. Outside established indications, treatment should be framed as research or specialist-led off-label care rather than standard wellness therapy.
“Investigational” is not a euphemism for “probably works but not yet approved.” It means the question is genuinely open, and some of these applications will not survive proper trials. Participating in a registered study is a legitimate and often admirable choice; paying privately for the same intervention outside one, without the monitoring or the contribution to knowledge, is a different proposition.
Related Aquila information
See our microbiome restoration therapy page for the approach offered at Aquila: screened donor microbiota, given as an oral drink, as tablets or by colonoscopy after a doctor's assessment. Be cautious with over-the-counter microbiome supplements marketed as equivalent to it.
Why home FMT is genuinely dangerous
Instructions for performing FMT at home using a known donor circulate online, generally aimed at people with chronic symptoms who feel medicine has not helped them. That frustration is understandable. The procedure is still not safe.
- A healthy-seeming donor can carry transmissible infections without symptoms.
- Home preparation involves no pathogen testing, quarantine or re-screening.
- Antimicrobial-resistant organisms transmit this way and have caused serious harm.
- Untested donor material can carry viruses and parasites that routine appearance does not exclude.
- There is no clinical oversight if something goes wrong.
The condition being self-treated is also usually one where FMT has no established benefit — meaning a real risk is being accepted for an unproven gain. Anyone considering this should discuss it with a doctor first, without expecting judgement.
Questions worth asking about any microbiome therapy
- What exactly is being administered — donor-derived material, a regulated product, or a supplement?
- What is its regulatory status in Singapore for this specific use?
- How were donors screened, and how recently?
- Is this an established indication or off-label? If off-label, on what basis?
- What evidence exists for this product and this condition?
- What is the plan if I develop symptoms afterwards?
“Microbiome restoration”, “gut reset” and “FMT” are used loosely in marketing. They can describe very different interventions with very different oversight, and it is reasonable to ask which one you are being offered.
Questions patients ask
Is FMT a treatment for every gut problem?
No. Evidence differs sharply between conditions, and for most proposed uses the question is still open. A defined clinical goal should come first.
Does Aquila offer microbiome restoration therapy?
Yes, after a doctor's assessment: for IBS symptom control, and alongside existing treatment for IBD, never as a replacement for it. See our microbiome restoration therapy page for how it works.
Can FMT help with IBS or weight loss?
For IBS, it may be considered after a doctor's assessment where the aim is better symptom control. Responses vary between individuals and are not guaranteed. For weight loss, the evidence does not support its use.
Does “investigational” mean it probably works?
No. It means the question is genuinely open, and some applications will not survive proper trials.
Is home FMT safe if I know and trust the donor?
No. A healthy-seeming donor can carry transmissible infections without symptoms, and home preparation involves no testing, quarantine or oversight.
Have there been serious harms?
Yes. FDA safety alerts have documented transmission of drug-resistant organisms to vulnerable recipients, which is why screening requirements became stringent.
Is donor screening a one-off?
No. Established programmes re-screen donors and quarantine material, releasing it only once subsequent testing is clear, because status can change.
Is FMT the same as taking probiotics?
No. They differ in composition, manufacturing, evidence and regulatory oversight, and should not be described interchangeably.
Is “microbiome restoration” the same as FMT?
At Aquila, yes. Microbiome restoration therapy uses screened donor microbiota on the same principle as FMT, given as an oral drink, as tablets or by colonoscopy. Elsewhere the term is used loosely, so it is reasonable to ask exactly what is being administered and under what oversight.
Could I inherit traits from a donor?
The long-term transfer of donor-associated characteristics is not fully characterised. Animal work on metabolic traits is a reason for caution about casual use.
Can I join a trial instead?
Where one exists for your condition, that is often the better route — you get monitoring, and the result contributes to answering the question.
What should I ask before agreeing to any microbiome therapy?
What exactly is administered, its regulatory status here, how donors were screened and when, whether the use is established or off-label, and the plan if problems arise.
Sources & further reading
This article is general educational information. FMT is a medical intervention requiring indication-specific assessment, donor and product screening and regulatory compliance. Home or informal FMT is unsafe. Availability and approved uses differ by jurisdiction. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 17 September 2026.
Microbiome therapy needs a defined indication
A gut-health consultation can clarify whether conventional investigation, lifestyle treatment or specialist microbiome care is appropriate.